Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
$114.42
$0.11(0.07%)
At close: 4:00 PM EST
$114.42
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$102.97 - $175.77
Previous CloseN/A
Volume111.19K
Average Volume (3M)918.38K
Market Cap
$6.45B
Enterprise Value$6.33B
Total Cash (Recent Filing)$767.63M
Total Debt (Recent Filing)$689.95M
Price to Earnings (P/E)188.5
Beta0.97
Next Earnings
May 05, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.49
Shares Outstanding56,331,110
10 Day Avg. Volume985,608
30 Day Avg. Volume918,381
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue8.57
Enterprise Value/Gross Profit16.83
Enterprise Value/Ebitda35.82
Forecast
1Y Price Target
$190.00Price Target Upside66.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)1.99
Revenue Forecast (FY)$826.93M
Bulls Say, Bears Say
Bulls Say
Account Strategy And Cross-sellingA focused account strategy targeting large pharmaceutical customers and CDMOs increases the potential for cross-selling and deeper product penetration within key accounts.
International ExpansionExpansion in Asia-Pacific, including a Singapore office and an enlarged Japan footprint, improves access to high-growth markets and creates new commercial opportunities.
Product InnovationMultiple new product launches across analytics, filtration, and protein franchises strengthen the bioprocessing portfolio and support potential top-line growth as customers adopt next-generation solutions.
Bears Say
Customer Ordering DelaysOrdering delays from pharmaceutical customers evaluating MFN-related deals are creating demand headwinds that may slow revenue momentum.
Guidance And Margin PressureConservative revenue and adjusted margin guidance that sits below some expectations could constrain near-term upside and keep pressure on the stock.
Visibility And Valuation RiskLimited visibility into longer-term growth drivers, combined with shares already reflecting robust growth and margin improvement, raises the risk that any slowdown could lead to negative re-pricing.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $102.97 and its highest was $175.77 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $6.45B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is May 05, 2026 which is in 38 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Feb 24, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.39.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,331,110 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.49 in its last earnings report, beating expectations of $0.44. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$190.00 (66.05% Upside)
$190.00 (66.05% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.93%
12-Months-Change
Fundamentals
Return on Equity
2.37%
Trailing 12-Months
Asset Growth
4.24%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and optimistic: management reported solid revenue acceleration (Q4 and full‑year growth above expectations), meaningful margin expansion, strong cash generation, successful product launches and acquisition integrations, and provided growth and margin guidance for 2026. The company also highlighted several near-term headwinds—muted capital equipment demand, a gene therapy customer-facing headwind, tariff and policy uncertainty, M&A/FX dilution to reported margins, and increased investments in Fit-for-Growth—that temper upside visibility. On balance, the positives (broad-based franchise strength, margin expansion, strong cash and funnel, and prudent but constructive guidance) substantially outweigh the cited risks.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$190.00
▲(66.05% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.59% Insiders
39.61% Mutual Funds
32.36% Other Institutional Investors
5.76% Public Companies and
Individual Investors